Ahmad Salehi, M.D., Ph.D.
  • Stanford, CA
  • United States
Share on Facebook
Share Twitter
  • NeuroNetwork Blog Posts
  • Events
  • Groups (1)

Ahmad Salehi, M.D., Ph.D.'s Groups

 

Ahmad Salehi, M.D., Ph.D.'s Page

Latest Activity

Ahmad Salehi, M.D., Ph.D. posted a group
Thumbnail

Down Syndrome

This group is dedicated to identifying gene or genes whose triplication leads to cognitive dysfunction in people with Down syndrome.See More
Sep 26, 2012
Ahmad Salehi, M.D., Ph.D. is now a member of The NeuroNetwork
Sep 26, 2012

Profile Information

Main areas of research:
Neurobiology of Down syndrome
Interests/keywords:
Down syndrome
PTSD
Locus coeruleus
Ts65Dn
Transgenic mice
Current title/position:
Clinical Associate Professor,
Current affiliation/employer:
Stanford Medical School
PhD Advisor and University:
Dick F Swaab, University of Amsterdam,
Postdoc Advisor and University:
WC Mobley, Stanford University
Personal or laboratory homepage:
http://ahmadsalehi.info
Publications:
Kleschevnikov AM, Belichenko PV, Salehi A, Wu C. Discoveries in Down syndrome: moving basic science to clinical care. Prog Brain Res. 2012;197:199-221.

Sanchez MM, D Das, JL Taylor, A Noda, JA Yesavage, A Salehi. BDNF polymorphism predicts the rate of decline in skilled task performance and hippocampal volume in healthy individuals.Translational Psychiatry 1 (10), e51.

Millan Sanchez M, SN Heyn, D Das, S Moghadam, Salehi A. Biological Psychiatry, 2011
Neurobiological Elements of Cognitive Dysfunction in Down Syndrome: Exploring the Role of APP. Biological Psychiatry, 2011. Featured on the cover.

Millan Sanchez M, S Moghadam, P Naik, KJ Martin, Salehi A. Hippocampal Network Alterations in Alzheimer's Disease and Down Syndrome: From Structure to Therapy-Journal of Alzheimer's Disease, 2011.

Zhan K, Hexin Xie, Gall J, Ma M, Griesbeck O, Salehi A, Rao J. Real-Time Imaging of Rab5 Activity Using a Prequenched Biosensor. ACS Chemical Biology, 2011

Delorey TM, Sahbaie P, Hashemi E, Li WW, Salehi A, Clark. Somatosensory and sen-sorimotor consequences associated with the heterozygous disruption of the autism candidate gene, Gabrb3. Behavioral Brain Research. 2010.

Salehi A, M. Faizi, D. Colas, J. Valletta, J. Laguna, R. Takimoto-Kimura, A. Kleschev-nikov, S. L. Wagner, P. Aisen, M. Shamloo, W. C. Mobley, Restoration of norepi-nephrine-modulated contextual memory in a mouse model of Down syndrome. Sci-ence Translational Medicine 1, 7ra17 (2009). Note: Featured on the cover.

Tamaki SJ, Jacobs Y, Dohse M, Capela A, Cooper J, Reitsma M, He D, Tushinski R, Belichenko PV, Salehi A, Mobley WC, Gage F, Huhn S, Tsukamoto AS, Weissman IR, Uchida N. Neuroprotection of Host Cells by Human Central Nervous System-Stem Cells in a Mouse Model of Infantile Neuronal Ceroid Lipofuscinosis. Cell Stem Cell. 5(3) 310-9. Note: Featured on the cover.

Honda M, Arai T, Fukazawa M, Honda Y, Tsuchiya K, Salehi A, Akiyama H, Mignot E. No ubiquitinated inclusions in hypocretin neurons of narcolepsy Patients. Neurology, 73(7); 511-517.

Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis B, Mount HTJ, Mufson EJ, Salehi A, Fahnestock M. High molecular weight amyloid-assemblies downregu-late brain-derived neurotrophic factor in transgenic mouse models of Alzheimer’s disease. Journal of Neuroscience. 22; 29(29):93.

Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, Salehi A, Hesla PE, Maehlen J, Gaus SE, Yanagisawa M, Sakurai T, Taheri S, Tsuchiya K, Honda Y, Mignot E. GFBP3 colocalizeswith and regulates hypocretin (orexin). PLoS ONE. 2009; 4(1):e4254.

Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, Mobley WC. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. Journal of Comparative Neurology. 2009 Feb 1; 512(4):453-66.

Salehi A, Faizi M, Belichenko PV, Mobley WC. Using mouse models to explore geno-type-phenotype relationship in Down syndrome. Mental Retardation & Developmen-tal Disability Research Review. 2007; 13(3):207-14
Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. Journal of Comparative Neurology. 2007 Oct 1; 504(4):329-45.

Salehi A, Jean-Dominique Delcroix, Pavel V. Belichenko, Ke Zhan, Chengbiao Wu, Janice S. Valletta, Ryoko Takimoto-Kimura, Alexander M. Kleschevnikov, Kumar Sambamurti, Peter P. Chung, Weiming Xia, Leyne C. Huang, Angela Villar, William A. Campbell, Laura Shapiro Kulnane, Ralph A. Nixon, Bruce T. Lamb, Charles J. Epstein, Gorazd B. Stokin, Lawrence S. B. Goldstein, and William C. Mobley. In-creased App expression in a mouse model of Down syndrome disrupts NGF trans-port and causes cholinergic neuron degeneration, 2006, Neuron, 52 (1) 29-42. Note: Among the top 20 papers (by download) from http://www.neuron.org/top20

Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, Mobley WC. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syn-drome. Journal of Comparative Neurology. 2004, 480(3):281-98.

Salehi A, Delcroix J.D., Swaab D. F. Alzheimer’s disease and NGF signaling. Journal of Neural Transmission. 2004,111(3):323-45.

Yesavage JA, Friedman L, Kraemer H, Tinklenberg JR, Salehi A, Noda A, Taylor JL, O’Hara R, Murphy G. Sleep/wake disruption in Alzheimer’s disease: APOE status and longitudinal course. Journal of Geriatric Psychiatry & Neurology. 2004,17(1):20-4.

Salehi A, Delcroix JD and Mobley WC. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends in Neuroscience. 2003, 26 73-80. Note: Among the top 10 most downloaded ScienceDirect articles in the field of neurosci-ence from http:/elsevierwrg.dmdelivery.nl/custom/md_articles/index.php

Verwer R.W., Hermens W.T., Dijkhuizen P., Ter Brake O., Baker R.E., Salehi A., Sluiter A.A., Kok M.J., Muller L.J., Verhaagen J., Swaab D.F. Cells in human postmortem brain tissue slices remain alive for several weeks in culture. FASEB Journal. 2002, (1):54-60.

Cooper J.D., Salehi A., Delcroix J.-D., Howe C.L., Belichenko P.V., Chua-Couzens J., Kilbridge J.F., Carlson E.J., Epstein C.J., Mobley W.C. Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenera-tive phenotypes following NGF infusion. Proceedings of National Academy of Sci-ences USA 2001, 98(18):10439-44.

Salehi A, Ocampo M, Verhaagen J. and Swaab D.F. P75 neurotrophin receptor in the nucleus basalis of Meynert in relation to age, sex and Alzheimer’s disease. Experi-mental Neurology. 2000, 61: 245-58.
Ishunina T.A., Salehi A., Swaab D. F. Sex- and Age- Related p75 Neurotrophin receptor expressionin the human supraoptic nucleus. Neuroendocrinology. 2000, 71: 243-51.

Van Leeuwen FW, Fischer DF, Kamel D, Sluijs JA, Sonnemans MA, Benne R, Swaab DF, Salehi A, Hol EM. Molecular misreading: a new type of transcript mutation ex-pressed during aging. Neurobiology of Aging. 2000, 21: 879-91.

Ishunina T.A., Salehi A., Hofman M.A. Swaab D.F. Activation of supraoptic nucleus in aging is sex dependent. Journal of Neuroendocrinology 11, 251-258

Salehi A., Swaab D.F. Diminished neuronal metabolic activity in Alzheimer’s disease. Journal of Neural Transmission, 1999, 106: 955-986.

Salehi A., Pool C.W., Mulder M., Gonatas N.K., Swaab D.F. Activity of hippocampal CA1 neurons in Alzheimer’s disease is not affected by the presence of adjacent neu-ritic plaques. Journal of Alzheimer's Disease, 1998, 1: 107-118. Note Selected sec-ond-best paper published in the journal.

Salehi A., Gonzalez Martinez V., Swaab D.F. A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer’s disease. Neurobiology of Aging, 1998, 19: 505-510.

Van Leeuwen F.W., deKleijn D.P.V., vandenHurk H.H., Neubauer A., Sonnemans M.A.F., Sluijs J.A., Koycu S, Ramdjiela R.D.J., Salehi A., Martens G.J.M., Grosveld F.G., Burbach J.P.H., Hol E.M. Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients: Transcript of live discussion, 28th May 1998 Alzheimer’s Reports 1998, 1: 271-274. Note Featured on the cover.

Salehi A., Bakker J., Mulder M., Swaab D.F. Limited effects of neuritic plaques on neu-ronal density in CA1 hippocamal area of Alzheimer patients. Alzheimer’s Disease & Associated Disorders. 1998 12, 77-82.
Oleana V.H., Salehi A., Swaab D.F. Increased expression of the TIAR protein in the hippocampus of Alzheimer patients. NeuroReport 1998 9: 1451-1454.

Van Leeuwen F.W., de Kleijn P.V., van den Hurk H., Neubauer A., Sonnemans M.A.F., Sluijs J.A., Köycü S., Ramdijelal R.D.J., Salehi A., Martens G.J.M., Grosveld F.G., Burbach P.H., Hol E.M.Framshift mutations of- amyloid precursor protein and ubiq-uitin-B in Alzheimer’s and Down Patients. Science 1998, 279: 242-247.

Salehi A., Dubelaar E.J.G., Mulder M., Swaab D.F. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer’s disease is ApoE type dependent. Pro-ceedings of the National Academy Science USA, 1998, 95: 11445-11449.

Lucassen P.J., Tilders F.J.H., Salehi A., Swaab D.F. Neuropeptides vasopressin (AVP), oxytocin (OXT) and corticotropin-releasing hormone (CRH) in the human hypothala-mus: activity changes in aging, Alzheimer’s disease and depression. Aging Clinical Experimental Research.,1997, 9 (Supplement to No#4) 48-50.

Swaab DF, Salehi A. The pathogenesis of Alzheimer disease: an alternative to the amy-loid hypothesis. J Neuropathol Exp Neurol. 1997 56(2):216. Journal of Neuropathol-ogy & Experimental Neurology 1996 55(10):1023-5.

Salehi A., Verhaagen J., Dijkhuizen P.A., Swaab D.F. Colocalization of high affinity neu-rotrophin receptors in nucleus basalis of Meynert neurons and their differential re-duction in Alzheimer’s disease. Neuroscience 1996 75, 373-387.

Salehi A., Van de Nes J.A.P., Hofman M.A., Gonatas N.K., Swaab D.F. Early cytoskele-tal changes as shown by Alz-50 are not accompanied by decreased neuronal activ-ity. Brain Research. 1995 678: 29-39.

Salehi A., Heyn S., Gonatas N.K., Swaab D.F. Decreased protein synthetic activity of the hypothalamic tuberomamillary nucleus in Alzheimer’s disease as suggested by smaller Golgi apparatus. Neuroscience Letters. 1995 193, 29-32.
Salehi A., Ravid R., Gonatas N.K., Swaab D.F. The decreased activity of hippocampal neurons in Alzheimer’s disease is not related to the presence of neurofibrillary tan-gles. Journal of Neuropathology & Experimental Neurology 1995 54, 704-709.

Lucassen P.J., Salehi A., Pool C.W., Gonatas N.K., Swaab D.F. Activation of vaso-pressin neurons in aging and Alzheimer’s disease. Journal of Neuroendocrinology 1994 6, 673-679.

Salehi A., Lucassen P.J., Pool C.W., Ravid R., Ganatas N.K., Swaab D.F. Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer’s disease as sug-gested by size of the Golgi apparatus. Neuroscience 1994 59: 871-880.

|PUBLICATIONS| Books Edited
Together with Van leeuwen FW, Giger RJ, Holtmaat AJGD and Verhaagen J. Neuronal Degeneration and Regeneration: From Basic Mechanisms to Prospects for Therapy. Progress in Brain Research. Vol 117 (1998) Elsevier, Amsterdam.

|PUBLICATIONS| Book Chapters
Salehi A, Wu C, Zhan K, Mobley WC. Axonal Transport of Neurotrophic Signals: An Achilles’ Heel for Neurodegeneration? In: Intracellular Traffic and Neurodegenerative Disorders (St. George-Hyslop, Mobley, Christen Eds). Research and Perspectives in Alzheimer’s Disease. IPSEN Foundation. 87-102.

Salehi A., Kleshevnikov A., Mobley WC. Cholinergic Neurodegeneration in Alzheimer’s Disease: Basis for Nerve Growth Factor Therapy. In “Pharmacological Mechanisms in Alzheimer’s Therapeutics” (Cuello AC. Ed). Spinger. pp 64-104

Salehi A., Pohlman B., Mobley WC. Down Syndrome / Trisomy 21. 2008. The New En-cyclopedia of Neuroscience. Elsevier.

Delcroix JD, Valletta J, Wu C, Howe CL, Lai CF, Cooper JD, Belichenko PV, Salehi A, Mobley WC. Trafficking the NGF signal: implications for normal and degenerating neurons. Prog Brain Res. Volume 146, 2004, Elsevier, Amsterdam pp 3-23.

Swaab D.F., Lucassen P.J., Salehi A., Scherder E.J.A., Van Someren E.J.W., Verwer R.W.H. Decreased neuronal activity and therapeutic strategies directed towards reactivation in Alzheimer’s disease. Proceeding the 6th International Conference on Alzheimer’s Disease and Related Disorders. Edited by Iqbal K, Swaab DF, Winblad B, Wisniewski HM. John Wiley & Sons Ltd, Chichester, 1999, pp 749-756.

Salehi, A., Dubelaar, E.J.G., Ishunina, T.A. and Swaab, D.F. - Neuronal activity and ge-netic background in Alzheimer’s disease. In: Iqbal, K., Swaab, D.F., Winblad, B. and Wisniewski, H.M. (Eds.), Alzheimer’s Disease and Related Disorders. Etiology, Pathogenesis and Therapeutics. John Wiley & Sons, Ltd., 1999, pp. 487-492.

Salehi A., Verhaagen J., Swaab D.F. Neurotrophin receptors in Alzheimer’s disease. Neuronal regeneration and regeneration: From Basic Mechanisms to Prospects for Therapy Edited by Van Leeuwen FW, Salehi A, Giger RJ, Holtmaat AJGD, Ver-haagen J. Prog. Brain Res. Vol 117, Elsevier, Amsterdam, 1998, pp, 71-89.

Ravid R., Swaab D.F., Kamphorst W., Salehi A. Brain banking and dementia research - The Amsterdam experience. Progress in Alzheimer’s and Parkinson’s disease. Ed-ited by Fisher et al. New York, Plenum Publishing,. 1998, pp 277-285.

Swaab D.F., Lucassen P.J., van de Nes J.A.P., Ravid R., Salehi A. Reduced neuronal activity is one of the major hallmarks of Alzheimer’s disease. In: Connections, Cogni-tion and Alzheimer’s Disease. Edited by Hyman B.T., Duyckaertes C. and Christen Y. Springer Verlag, Berlin,1997, 83-104.

Ravid R., Swaab D.F., Van Zwieten E.J., Salehi A. Controls are what makes a brain bank go round. Neuropathological diagnostic criteria for brain banking. 1995. 4-13

Comment Wall

You need to be a member of The NeuroNetwork to add comments!

Join The NeuroNetwork

  • No comments yet!
 
 
 

© 2014   Created by Springer.

Badges  |  Report an Issue  |  Terms of Service